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Abstract
Introduction: The aim of this study was to analyse the influence of factors reported in the minimum
histopathology dataset for colorectal liver metastases (CRLM) and other pre-operative factors compared
with additional data relating to the presence of tumour pseudocapsules and necrosis on recurrence 1 year
after a resection.
Methods: For a period of 14 months, extended histological reporting of CRLM specimens was per-
formed, including the presence of pseudocapsules and necrosis in each tumour. The details of recurrence
were obtained from surveillance imaging.
Results: In 66 patients there were 27 recurrences within 1 year. The rates were lower for patients with
tumour pseudocapsules (8/27) than for patients without (19/36) (P = 0.030). Pseudocapsules were
associated with a younger age (P = 0.005), nodal stage of the primary colorectal tumour (P = 0.025) and
metachronous tumours (P = 0.004). In patients with synchronous disease and pseudocapsules, the
recurrence rate was 2/12 compared with 13/23 patients without pseudocapsules (P = 0.026).
Discussion: These findings demonstrate that histological examination of resection specimens can
provide significant additional prognostic information for patients after resection of CRLM, compared with
clinical and radiological data. The present finding that the absence of a pseudocapsule in patients with
synchronous CRLM is associated with a dramatically worse outcome may help direct patient-specific
adjuvant treatment and care.
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Introduction
Although resection of colorectal liver metastases (CRLM) offers
overall 5-year survival rates ranging from 32–65%,1,2 there is a
spectrum of outcomes after surgery with some individuals
remaining disease free and potentially being cured, whereas
others will recur early with a poor outcome.3,4 A number of risk
scoring systems exist to stratify patients according to likely 5-year
survival. These systems predominantly use factors measurable
pre-operatively which have been shown to be markers of
prognosis, such as carcinoembryonic antigen (CEA) estimation,5
tumour number,5–15 tumour size,5,12–15 resection margin
clearance,5,8–10,12,16–20 the presence of satellite lesions18 and the
ratio of neutrophils to lymphocytes amongst white cells in a full
blood count measured pre-operatively.21 Liver specimens are rou-
tinely sent for pathological analysis after resection and the UK
Royal College of Pathologists (RCPath) minimum dataset for
liver specimens with colorectal metastases includes details of
tumour number, size, location, resection margin clearance, cap-
sular invasion, degree of differentiation, the presence of tumour
necrosis, vascular and lymphatic invasion, the presence of satel-
lite lesions, invasion of adherent tissue and lymph node status if
sampled.22 With regards to prognostic factors, the most impor-
tant additional information the pathology report reveals which is
not available pre-operatively is the resection margin status.
However, of the 15 risk scoring systems available, only 3 have
shown the presence of an involved resection margin to be a sig-
nificant prognostic factor.23 Therefore histological examination
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of CRLM specimens may add relatively little additional prognos-
tic information compared with clinical, radiological and labora-
tory data in the currently used scoring systems.
Extended examination of resection specimens may reveal other
features whose prognostic significance has not been rigorously
assessed, including details of a fibrous pseudocapsule around the
tumour and the degree of tumour necrosis. The presence of a
pseudocapsule has been associated with a better overall survival
after resection of CRLM.24–26 Tumour necrosis can result from
chemotherapy use27 and is also seen in tumours with high rates of
cellular turnover in rapidly expanding tumours.28 Therefore
tumour necrosis may be associated with more aggressive tumours
and a worse prognosis.
The aim of this study was to analyse the relative significance of
factors reported in the minimum histopathology dataset and
other pre-operative factors compared with additional data relat-
ing to the presence of tumour pseudocapsules and necrosis on
tumour recurrence 1 year after resection of CRLM.
Methods
Between March 2010 and May 2011, the Histopathology Depart-
ment at Derriford Hospital performed extended reporting of
CRLM specimens as an experimental protocol. Histology reports
documented the presence or absence of a pseudocapsule, as well as
how much of each tumour diameter was encompassed (zero,
<50% or >50%). The presence and degree of necrosis observed in
each tumour (nil, <33%, 33–66% and complete necrosis) was also
recorded. Up to a maximum of the three largest tumours in each
patient were assessed and relevant features recorded. The pseudo-
capsule was identified as a paucicellular collagenous band present
between the tumour cells and the adjacent hepatocytes, which
measured at least 0.1 mm in thickness (Fig. 1). Tumour necrosis
was characterized as discrete foci of cellular debris indicative of
coagulative cell death (Fig. 2). A proforma was designed and
agreed within the Histopathology department to standardize
reporting of resection specimens. In cases of heterogeneity
between tumours, the amount of pseudocapsule in up to the three
largest tumours was measured and an average figure calculated
according to a simple formula (>50% = 2, <50% = 1, no pseudo-
capsule = 0) and used in analyses. The amount of necrosis was
determined for the largest lesion only.
All patients underwent tumour staging with a computed tom-
ography scan prior to surgery. In addition, 46 patients had a
pre-operative magnetic resonance imaging (MRI) scan and 50
patients a pre-operative positron emission tomography (PET)
scan, at the discretion of the referring clinician.
A prospective database is maintained of all patients undergo-
ing resection for CRLM and a review of these patients was per-
formed when all had been followed up for a minimum of 1 year.
The database holds information on primary histology, timing
of detection of metastatic disease (synchronous tumours were
defined as those discovered pre-operatively or within 2 months
of primary surgery), the neutrophil to lymphocyte ratio, the use
of chemotherapy as well as the histological features of the
resected CRLM. Details of tumour recurrence were identified
from surveillance imaging which is performed according to pub-
lished guidelines.22 CEA estimation was not used routinely in
post-operative surveillance. One patient did not have surveillance
imaging in the first post-operative year and was excluded from
recurrence analysis. One-year recurrence was chosen as the
primary end point because a high proportion of CRLM recur
within this timeframe and early recurrence is associated with a
worse overall survival.3,4
Potential associations between 1-year tumour recurrence and
clinical and histological characteristics were tested initially using
Figure 1 Pathological examination showing a pseudocapsule (PC),
non-neoplastic liver (NL) and a colorectal liver metastasis (CRLM).
Original magnification x50 using haematoxylin and eosin stain
Figure 2 Pathological examination showing tumour necrosis (TN) in
colorectal liver metastases (CRLM). Original magnification x50 using
haematoxylin and eosin stain
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univariate logistic regression or the chi-square test at the level of
P < 0.25,29 as appropriate. The association between clinical and
histological characteristics and the presence of a tumour pseudo-
capsule in individual tumours was tested in a similar fashion.
Significant variables in the univariate analysis were included in the
multivariate logistic regression model and were considered to be
significant if P < 0.05. All analyses were carried out using the
statistical package R 2.1.14.30
Results
Sixty-six patients were identified who underwent surgery for
CRLM of whom 65 were available for recurrence analysis. Addi-
tional staging MRI scans were performed in 28 of 38 patients with
synchronous tumours and 18 of 28 with metachronous tumours
(P = 0.431). Additional staging PET scans were performed in 28 of
38 patients with synchronous tumours and 22 of 28 with meta-
chronous tumours (P = 0.774). The median number of surveil-
lance scans performed was one (1–4) in patients who recurred and
two (1–5) in patients who had not recurred at 1 year.
In addition to surgery, four patients had intra-operative radi-
ofrequency ablation (RFA). Six patients died of recurrent cancer
in the first year of follow-up. Twenty-eight patients (43.1%) devel-
oped recurrent cancer within the first year of follow-up. Eight of
these recurred in the liver only, 12 had extrahepatic recurrence
only and 8 had both hepatic and extrahepatic recurrence. Patient
characteristics are displayed in Table 1.
From the total patient group, 132 lesions were examined histo-
logically in the extended dataset. In two patients, three tumours
had responded completely to chemotherapy and were only iden-
tifiable microscopically as areas of complete necrosis. In these
tumours, the presence of a pseudocapsule could not be assessed.
Histological details of the resected specimens including the
RCPath dataset and the presence of a pseudocapsule and degree of
tumour necrosis for the 65 patients included in the recurrence
analysis are shown in Table 2. Heterogeneity in the presence of
tumour pseudocapsules in multiple metastases was observed in 6
of 27 patients, where pseudocapsules were absent in some
tumours, and in 5 of 27 patients where a differing amount of
pseudocapsule was noted between tumours.
Analysis of factors associated with 1-year recurrence
in 65 patients
Univariate analysis of pre-operative and histological factors and
1-year recurrence revealed potential associations with age, number
of metastases, a resection margin of less than 1 mm and the pres-
ence or absence of a pseudocapsule (P < 0.250) (Table 3). Multi-
variate analysis revealed that only the absence of a pseudocapsule
and a resection margin of less than 1 mm were significantly asso-
ciated with early tumour recurrence (Table 3). One-year recur-
rence rates were lower for patients with tumour pseudocapsules
(8/27) than for patients with no pseudocapsule (19/36) (P= 0.030).
There was no significant difference in tumour recurrence rates
according to the amount (< or >50%) of pseudocapsule present (P
= 0.750) (Fig. 3). The recurrence rate in patients with a resection
margin of <1 mm was 13/22 compared with 15/43 in those with a
margin of >1 mm (P = 0.045).
Table 1 Pre-operative details of 66 patients undergoing extended histological reporting of resection of hepatic colorectal metastases
n = 66 Median (range) Count (%)
Age 65 (33–84)
Gender Male 40 (60.6)
Female 26 (39.4)
Primary T stage 0 2 (3.0)
1 3 (4.5)
2 7 (10.6)
3 29 (43.9)
4 23 (34.8)
Unavailable 2 (3.0)
Primary N stage 0 34 (51.5)
1 18 (27.2)
2 11 (16.7)
Unavailable 3 (4.5)
Timing Synchronous 38 (57.6)
Metachronous 28 (42.4)
Liver-directed chemotherapy Synchronous 35 (92.1)
Metachronous 11 (39.2)
Neutrophil lymphocyte ratio Less than 5 57 (86.4)
More than 5 9 (13.6)
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Analysis of factors associated with the presence of a
pseudocapsule in 132 tumours
Uni- and multivariate analysis was undertaken and revealed that
increasing age, nodal status of the primary colorectal cancer and
metachronous liver metastases were associated with the presence of
a tumour pseudocapsule (Table 4). The size of individual tumours
was not associated with the presence of a pseudocapsule. For each
year of age the incidence of a pseudocapsule falls by 0.073 (Fig. 4).
Similarly as the N stage increases by 1, the incidence of a pseudocap-
sule falls by 0.566 (Fig. 5).Pseudocapsules occurred more commonly
in tumours with a metachronous presentation (25/51) compared
with a synchronous presentation (20/81) (P = 0.004). Resection
margin positivity was noted in 11 of 52 tumours with a pseudocap-
sule and 8 of 77 tumours without a pseudocapsule (P = 0.105).
The presence of a pseudocapsule had no significant association
with 1-year recurrence in patients with metachronous CRLM.
However, in individuals with synchronous lesions the presence of
a pseudocapsule was associated with a lower 1-year recurrence
rate (2/12 versus 13/23) (P = 0.026) (Table 5).
Discussion
The principal finding of this study is that a fibrous pseudocapsule
is a common histological feature in patients undergoing resection
Table 2 Histopathological features and 1-year recurrence of 65 patients undergoing extended histological reporting of resection of hepatic
colorectal metastases with 1-year follow-up
n = 65 1-year recurrence
No (n = 37) Yes (n = 28)
Median
(range)
Count Median
(range)
Count
Number of lesions identified 2
(1–10)
3
(1–10)
Max diameter at histology (mm) 27
(3–119)
43
(7–120)
Satellite lesions Yes (0) 0 0
No (65) 37 28
Margin less than 10 mm Yes (45) 24 21
No (20) 13 7
Margin less than 1 mm Yes (22) 9 13
No (43) 28 15
Liver capsule smooth and intact Yes (55) 33 22
No (10) 4 6
Invasion of adherent tissue Yes (1) 0 1
No (64) 37 27
Differentiation No tumour (3) 2 1
Well/moderate (62) 35 27
Vascular invasion Yes (9) 3 6
No (56) 34 22
Histological evidence of response to chemotherapy No response (4) 2 2
Response (19) 13 6
Uncertain (7) 4 3
Not recorded (35) 18 17
Average amount of pseudocapsule Nil (36) 17 19
<50% (17) 12 5
>50% (10) 7 3
N/A (2) 1 1
Amount of necrosis of the largest tumour Nil (4) 3 1
<33% (29) 16 13
33–66% (21) 13 8
>66% (11) 5 6
In two patients (three tumours) a complete response to chemotherapy was noted and therefore a pseudocapsule could not be identified (NA).
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of CRLM and is associated with a lower 1-year tumour recurrence
rate. This study extends earlier reports by showing that the benefit
of a pseudocapsule occurs predominantly in patients with syn-
chronous hepatic metastases. In these patients, only one-third
develop a pseudocapsule but have a dramatically reduced inci-
dence of 1-year tumour recurrence (2/12) compared with patients
without a pseudocapsule (13/23). The study also confirms that the
presence of an involved resection margin is an independent pre-
dictor of early tumour recurrence. These two findings demon-
strate that histological examination of resection specimens can
provide significant additional prognostic information for patients
after resection of CRLM, compared with clinical and radiological
data available pre-operatively.
The strength of the study lies in its prospective and unselected
design, including all patients over a defined period with stand-
ardization of reporting within predetermined guidelines. Speci-
mens were reported by pathologists with a subspecialty interest
in gastrointestinal disease who collectively approved the experi-
mental protocol. The value of these findings to clinical practice
is significant as the identification of a tumour pseudocapsule
is readily performed on standard histology specimens without
the need for special stains. A potential weakness of the study is
that estimation of the extent of the pseudocapsule is subjective
and semi-quantitative; however, the present data show that the
extent of the pseudocapsule is less important than its simple
presence.
Although three previously published studies have shown that
the presence of a pseudocapsule is associated with improved long-
term survival after resection of CRLM24–26 it is not commonly
reported in this setting. Our series is the first to report lower
recurrence rates in the presence of a tumour pseudocapsule in a
Western population and adds further evidence of the benefit of
adding this finding to the core data set in histology reporting of
CRLM. Further follow-up will determine if lower early recurrence
rates in this group are associated with an improved survival.
Table 3 Univariate and multivariate analysis of pre-operative and histological factors affecting 1-year recurrence after resection of hepatic
colorectal metastases in 65 patients
Factor (n = 65) Univariate
P-value
Multivariate
P-value
Incidence
ratio (95% CI)
Age 0.025a 0.876
Gender 0.506
Max diameter of tumour at histology 0.323
Number of lesions 0.240a 0.831
Capsule smooth and intact 0.408
Margin less than 1 mm 0.109a 0.045b 2.89 (1.61– 5.18)
Margin less than 10 mm 0.545
Histological response to chemotherapy 0.674
T stage of primary tumour 0.571
N stage of primary tumour 0.381
Synchronous versus metachronous 0.824
Liver directed chemotherapy (yes/no) 0.710
Neutrophil lymphocyte ratio (>5) 0.320
Pseudocapsule present 0.114a 0.030b 0.30 (0.174–0.524)
Necrosis of largest lesion 0.886
aSignificant at the level of 0.25 for univariate analysis and included in multivariate analysis.
bSignificant at the level of 0.05 for multivariate analysis.
No pseudocapsule
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Figure 3 Probability of 1 year recurrence according to the amount of
pseudocapsule present for 65 patients undergoing extended histo-
logical reporting of resection of hepatic colorectal metastases. No
significant difference between <50% and >50% (P = 0.75)
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It is not known what stimulates the formation of a fibrous
pseudocapsule and what role it plays in preventing early recur-
rence. The capsule develops at the interface between tumour tissue
and normal liver tissue and the proliferating stromal cells in the
capsule have been shown to be myofibroblasts.26 It has been sug-
gested that CRLM activate hepatic stellate cells to form myofibrob-
lasts and that this is a host defence response, similar to an
inflammatory response, creating a mechanical and chemical
Age (years)
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0.4
0.2
0.0
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y
<50 50–60 60–70 >70
Figure 4 Probability of pseudocapsule presence according to age
for 132 tumours in patients undergoing resection of hepatic color-
ectal metastases
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Figure 5 Probability of a pseudocapsule according to N stage of
primary colorectal tumour for 132 tumours in patients undergoing
resection of hepatic colorectal metastases
Table 4 Univariate and multivariate analysis of factors associated with the presence of a tumour pseudocapsule (n = 132) in 66 patients
undergoing resection of hepatic colorectal metastases
Factor (n = 132) Univariate
P-value
Multivariate
P-value
Incidence ratio
(95% CI)
Age (per year) 0.011a 0.005b 0.937 (0.90–0.98)
Gender 0.090a 0.142
T stage of primary tumour 0.290
N stage of primary tumour <0.001a 0.025b 0.434 (0.24–0.77)
Metachronous versus synchronous 0.004a 0.004b 2.622 (1.13–6.09)
Neutrophil lymphocyte ratio 0.348
Tumour size 0.167a 0.405
Resection margin < 1 mm 0.150a 0.105
aSignificant at the level of 0.25 for univariate analysis and included in multivariate analysis.
bSignificant at the level of 0.05 for multivariate analysis.
Table 5 Relationship between pseudocapsule and 1-year recurrence in synchronous and metachronous lesions in patients undergoing
resection of hepatic colorectal metastases
n = 65 1-year recurrence
No Yes P-value
Timing Synchronous (37) Pseudocapsule Absent (23) 10 13 0.026a
Present (12) 10 2
N/A (2) 1 1
Metachronous (28) Pseudocapsule Absent (13) 7 6 0.521
Present (15) 9 6
aSignificant at the level of 0.05 on Fisher's exact test.
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barrier around the tumour preventing further vascular and intra-
biliary invasion.26 The present finding that the absence of a tumour
pseudocapsule is associated with a more aggressive primary
tumour with nodal metastases supports this hypothesis, although
we did not find any association with the neutrophil to lymphocyte
ratio among circulating leucocytes, which has also been shown to
be a marker of an inflammatory response to the tumour.21 It is also
possible that older patients are less able to generate an inflamma-
tory response to the tumour, accounting for the finding of a smaller
proportion with tumour pseudocapsules in this age group.
The present finding that the absence of a pseudocapsule in
patients with synchronous CRLM is associated with a higher
tumour recurrence may help direct patient-specific adjuvant
treatment and care. For example, these patients may benefit from
an increased frequency of post-operative imaging surveillance.
Although post-operative chemotherapy after resection of CRLM
has been shown to be of a limited value,31 future trials of this
modality may be developed to target treatment to high-risk
groups, such as patients with synchronous tumours with no
pseudocapsules.
Further research needs to be undertaken to confirm the poten-
tial association of a lower tumour recurrence rate in patients with
tumour pseudocapsule in larger series, in addition to correlating
this finding with improved survival. Further data may allow the
development of a risk scoring system incorporating this finding.
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